To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies

计划入组 374 人 · 首次发布于 2026 年 9 月 16 日

Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy

Validation of the IgA1 Detection Method With Gradient Glycosylation by Mass Spectrometry as a Potential Marker of Renal Involvement in Pediatric Rheumatoid Purpura

计划入组 52 人 · 首次发布于 2020 年 12 月 7 日

IgA proteases(IGAN Biosciences)

IgG1 Ab1

PfSPZ-GA1

Biohaven's BHV-1400 Demonstrates Rapid Reduction of Gd-IgA1 in Phase 1 Trial for IgA Nephropathy

Felzartamab Shows Promise in Reducing Proteinuria in IgA Nephropathy Patients

Paradigm Shift in IgA Nephropathy Treatment: Novel Targeted Therapies Address Disease Mechanisms